




# Patient portals and EHR portability: Moving data with the patient

**Gil Alterovitz, PhD, FACMI**



# Patient Portals

- Online website or mobile application
- Secure storage and access to personal health/medical information



MyChart  
Your secure online health connection

Welcome, Nathan  [Log Out](#)

Nathan (Me)

Home  
My Medical Record  
Message Center  
Appointments  
My Family's Records  
Administrative  
Preferences

Health Library  
Find information on:  
  
NLM Search

ANDROID APP ON Google play  
Available on the App Store

**You Might Want To**

PAGOSA SPRINGS Medical Center  
Better health and wellness where you live

Health Record Messaging Appointments

Medical Center Website Health Library  
CDC Preventative Care Donate to Foundation

JANE SMITH  
Change person

Allergies  
none

Latest Results

Coagulation

PT POC  
10  
May 23, 2017

INR POC  
1.2  
May 23, 2017

[View Results](#)

HealtheLife  
Safe. Secure. Portable.  
Get it on your mobile device today!

Available on the App Store GET IT ON Google play

Coming soon... Users will can choose to display their measurements in metric units (cm, kg) or imperial units (inches, lbs). Keep an eye out for this new feature.

# Portal Limitations

- **Few use cases**

- Many portals originally designed as one way communication of lab results to patients.
- Typically designed for patients to use on their own, before/after health care visits
- Lack of integration of complex/genomic information

- **Closed environments**


- Hard to add new use cases (often depends on EHR vendor)
- Closed environment can prevent third-party innovation
- Limited ability for analytics
- Interoperability issues
- Access may be limited (e.g. based on coverage, provider, etc.)



**SORRY, SON...THERE'S NO APP FOR THAT**

There are many use cases in genomics...

# Use Cases: “HL7 Domain Analysis Model: Clinical Sequencing”



- Publication contains list of use cases and workflows for clinical genomics- with focus on clinical sequencing
- Published Feb 2017
- Work has formed basis for several national/international programs
- Used as guide for analyzing use cases by a number of provider institutions.

<https://www.healthcare-informatics.com/news-item/interoperability/hl7-publishes-domain-analysis-model-clinical-sequencing>

# Some Key Use Cases

## **Family History**

Estimating disease risk using germline tests, family pedigree, and clinical data

## **Precision Cancer**

Somatic (tumor) sequencing for diagnosis/prognosis

## **HLA Typing**

Immunogenomic sequencing for organ matching, etc.

## **NGS Assay Evaluation/Regulatory**

Benchmarking NGS quality of vendor to “gold standard”

## **Pharmacogenomics**



Germline and somatic sequencing for drug selection, rejection, dosing

And, patients want to be engaged in their own care and data use/sharing...





**ACTUALLY, DAD... THERE'S A NUMBER OF APPS FOR THAT.**




# UBER FOR SNOW PLOW APP

## A SNOW CLEARING APP TO MAKE YOUR WINTERS A BREEZE!


Get ready to make the most of the newest opportunity in the service industry by investing in the Uber for snow removal app. Make your clients snow problems disappear and line your pockets at the same time!

And, the same may become true for  
genomics by creating an EHR ecosystem...

# Apps



**SMART Genomics Advisor**




**SMART Precision Cancer Medicine**

Alterovitz, et al, SMART on FHIR Genomics: Facilitating standardized clinico-genomic apps, JAMIA, 2015.

Also, providers want to leverage extra-EHR  
resources/services

# SMART Cancer Navigator

- A Framework for Implementing ASCO Workshop Recommendations to Enable Precision Cancer Medicine
- Securely links patient-specific data from EHRs via FHIR and multiple laboratory/reference knowledge bases for information and treatment options.



<https://smart-cancer-navigator.github.io>

J Warner, I Prasad, M Bennett, M Arniella, A Beeghly-Fadiel, K Mandl, and G Alterovitz, SMART Cancer Navigator: A Framework for Implementing ASCO Workshop Recommendations to Enable Precision Cancer Medicine, JCO Precision Oncology 2018:2, 1-14.



How do we enable this?

# Moving Forward


- **Few use cases -> Many use cases**
  - Enable an apps, app stores ecosystem
- **Closed environments -> Open environments to foster innovation**
  - Enable standards-based environments and tools





How best to engage with  
**genomics lab results**  
to improve patient care?

# Data buried in PDFs, or ...



**ST. August of Ribó**  
123 Avenue Hospital DR | La Jolla | CA 92122

Gregory House  
1 Princeton-Plainsboro Teaching Hospital  
Princeton, NJ, 12345

**Medical Faculty**  
Director:  
**Dr. Robert Kelso**  
Tel. 858 123 4567  
Fax. 858 999 9999

Head of Department  
**Dr. Percival Cox**  
Tel. 858 124 4567  
Fax. 858 999 9999

**Oncogenomics Report for Patient SRR1027184**

Name: Peppermint Patty      Date of birth: 01.01.1990  
Address: 123 Cray Court, San Diego, CA, 12345

Clinical Diagnosis: Breast Cancer      Stage: III  
Molecular-subtype: HER2      Receptor-status: HER2 + ER- PR-  
Date of first Diagnosis: 01.01.1999

Sampling-Date:	05.01.1999
Sample volume:	100 ml
Purity:	88%
Amount of RNA used:	25 ng
Seq-Type(s):	RNA-Seq
Seq-Protocol(s):	Illumina total RNA-Seq

**FDA Approved Therapies (in patients tumor type)**


Target	Drugs	Diff	Mut	Fus	PW
ESR1	Fulvestrant Tamoxifen	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Table 1: Diff: arrow indicates if target is up- or downregulated. Mut: if checked, drug targets known mutation. Fus: if checked, drug targets fusion. PW: if checked, target is member of altered pathway

**FDA Approved Therapies (in another tumor type)**

Target	Drugs	Diff	Mut	Fus	PW
ANXA1	Dexamethasone	<input type="checkbox"/>	<input type="checkbox"/>		
AR	Flutamide Nilutamide Bicalutamide Enzalutamide	<input type="checkbox"/>	<input type="checkbox"/>		
ESR1	Fluocymesterone	<input type="checkbox"/>	<input type="checkbox"/>		
FCGR1A	Porfimer Methyl aminolevulinate	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
GNRHR	Abarelix Degarelix	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
MMP11	Marimastat	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
MMP13	Marimastat	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
TYR	Azelaic Acid Mimosine	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	

Table 2: Diff: arrow indicates if target is up- or downregulated. Mut: if checked, drug targets known mutation. Fus: if checked, drug targets fusion. PW: if checked, target is member of altered pathway



Contextualized, dynamic, actionable,  
and re-computable results in ...



# Structured data, enabling analytics...

```
{
  "$schema": "http://json-schema.org/draft-04/schema#",
  "definitions": {
    "variant": {
      "type": "object",
      "properties": {
        "seq_id": {"$ref": "#/definitions/sha512_20"},
        "span": {"$ref": "#/definitions/span"},
        "alt": {"$ref": "#/definitions/sequence"}
      },
      "required": ["seq_id", "span", "alt"]
    },
    "sequence": {
      "type": "string",
      "pattern": "^[A-Z]$"
    },
    "sha512_20": {
      "type": "string",
      "pattern": "^[0-9abcdef]$",
      "minLength": 20,
      "maxLength": 128,
    }
  }
}
```



< Patient Search

Patient name

(MRN: )


Male,   
Diagnosis: Lung Cancer  
Mutation: KRAS G12C

Date of birth


Medical record number

Warner & Alterovitz. SMART Precision Cancer Medicine, JAMIA, 2016.

Mutated Genes Observed in Lung Cancer



Observed Variants in Lung Cancer Patients with KRAS Mutation



For a specific gene mutation in a specific lung cancer patient, show information for most common KRAS in *lung cancer* populations

# Vision

## **Unified Clinical and Genomic Data Standard**

clinical data ♦ genomics (omics) ♦ precision medicine


## **Modern Technology**

web-friendly ♦ RESTful ♦ resource-based

## **Workflow Ready**


queryable ♦ granular ♦ on-demand

# Fast Healthcare Interoperability Resources (FHIR)




# Incremental Adoption of FHIR Genomics

Traditional  
Labs



NGS  
Labs







Observation  
+ LOINC codes

Observation Genetics Profiles

+ Family History/Other  
resource profiles

Sequence Resource

+ Repository Reads





# Precision Medicine Initiative (All of Us) Cohort Program RFA

Describe potential utilization of current and emerging standards to facilitate data exchange and analysis, such as:


- Standards for capture and representation of family health history such as SNOMED CT and HL7 Version 3 Implementation Guide: Family History/Pedigree for familial relationships.
- HL7 DIGITiZE Actions Collaborative draft LOINC specification for pharmacogenomics.
- HL7 Clinical Genomics WG standards including CDA R2 Clinical Genetics Reporting, Clinical Genomics Pedigree Model, HL7 Genetic Testing Results Message (V2), and Clinical Sequencing Domain Analysis Model (DAM).
- **SMART on FHIR Genomics** standards to support development of clinico-genomic apps to communicate clinical genomics data between EHR systems.
- Open ID Connect, OAuth and UMA for individual authorization and authentication
- More complete authorization standards (e.g., IHE XUA, IUA, etc.) to ensure authorization standards are compatible across disparate networks.
- Global Alliance for Genomics and Health (GA4GH) standards to address computable consent for

**SMART on FHIR Genomics** standards to support development of clinico-genomic apps to communicate clinical genomics data between EHR systems.



Alterovitz, et al, SMART on FHIR Genomics: Facilitating standardized clinico-genomic apps, JAMIA, 2015.

# SMART on FHIR



## API

Resource oriented, everything a **URL**



## Data Model


Context (container, user, patient)

Medical (problems, allergies, ...)



## Authentication

Consistent delegation, web standards (OAuth)




## UI

Standards-based integration (HTML5)



# SMART on FHIR




## API

Resource oriented, everything a **URL**




## Data Model

Context (container, user, patient)  
Medical (problems, allergies, ...)



## Authentication

Consistent delegation, web standards (OAuth)




## UI


Standards-based integration (HTML5)



# SMART on FHIR on Genomics




# SMART on FHIR on Genomics




Moving data in and out of native systems to third-party apps

# SMART on FHIR with Genomics




# Landscape of Adoption Programs and Iterative Genomics Standard Feedback




# Toward a Genomics-Empowered Ecosystem

- Move away from point-to-point thinking toward networked ecosystem
- Need ability to communicate in heterogeneous ecosystem with multiple parties
- Create ability to communicate different levels of clinical genomic information
- Create metrics for measuring different speed in adoption





# SMART on FHIR Pilots Ecosystem Example




- Org. support SMART/FHIR
- Org. pilots of SMART/FHIR

Data Sharing to Support the Cancer Journey in the Digital Era. Journal of oncology practice, 2016.

# **Pathway toward Clinical and Genomic Integration**


# Single National Standard for Clinical Care & Research




---



**Where do genomics results go?**



# Precedent



# Looking Forward...

- SMART on FHIR-powered cloud-based servers with patient apps
  - App stores enable patients to customize experience based on needs
    - Patient ability to control information sharing in real-time for clinical/genomic information.
- Apps that enable patients and providers to “collaborate” on care
  - Screens built for provider-patient engagement
- Apps designed for genomic care coordination
  - Patient control of information/sharing

Gil Alterovitz  
[ga@alum.mit.edu](mailto:ga@alum.mit.edu)

LinkedIn:

